News Sentiment

ABVX sentiment intelligence

Abivax SA American Depositary Shares news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 60 Balanced news tone 57 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 136.65 Week of 17 Jul 2026
Weighted tone 60/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

76/100 classification confidence.

Company focus 48

directly relevant articles

Source quality 6

high-authority source matches

Trend context Trend inactive

-2.3% over one week, +37.8% over four weeks, trend inactive, and materially above fair value.

Latest direct headline Neutral

Abivax SA Sponsored ADR $ABVX Shares Bought by Jennison Associates LLC

Market Reaction

Balanced read

69/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 76/100 classification
One-week reaction -2.3% Price reacting lower
Trend fit Trend inactive 37.8% over four weeks
Fair value 199.0% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 27
Neutral 26
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 48
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 17
MarketBeat 5
MT Newswires 4
CNBC 3
MSN 2
Quartz 2
Stock Titan 2
Stocktwits 2

Event Lens

What the news is about

Classified themes
Market update 25
Earnings 17
Deals and strategy 4
Analyst action 3
Regulatory and legal 2
Guidance 2
Macro sensitivity 2
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-57 of 57
Stocktwits Direct company coverage

Abivax Prices $800M Offering Of ADS – Here’s A Look At Some Key Figures

Abivax announced the pricing of an upsized underwritten public offering of 6.4 million American Depositary Shares (ADSs) at $125 each, increasing the offering size from $600 million to $800 million. The company expects these proceeds, combined with existing cash, to extend its op

Tone
Positive 73/100
Event
Guidance
Published
02 Jul 2026 09:09
Source
Stocktwits
WSJ Direct company coverage

Abivax Shares Continue Climbing After Biotech Firm Moves to Bolster Balance Sheet

Abivax shares continued to rise after the French biotech firm announced an upsized stock offering to strengthen its balance sheet. This move follows positive clinical trial data for its lead drug, obefazimod, which is being developed to treat inflammatory bowel diseases. The comp

Tone
Positive 73/100
Event
Market update
Published
02 Jul 2026 09:09
Source
WSJ
BioPharma Dive Direct company coverage

Abivax shares surge as worries subside over immune drug’s cancer risk

Shares of Abivax surged by nearly 40% after the release of supplementary Phase 3 data for its inflammatory bowel disease drug, obefazimod, which alleviated investor concerns about increased cancer risk. The company stated that cancer rates observed in its trials were consistent w

Tone
Neutral 50/100
Event
Macro sensitivity
Published
01 Jul 2026 22:12
Source
BioPharma Dive
Quartz Direct company coverage

Abivax stock surges on obefazimod safety data, cancer concerns

Abivax's stock price experienced a surge following the release of safety data for its drug candidate, obefazimod. This positive development likely addressed some previous concerns, potentially including those related to cancer.

Tone
Positive 71/100
Event
Market update
Published
01 Jul 2026 21:10
Source
Quartz
Market source Direct company coverage

From Cancer Scare to Comeback, Abivax Shares Erase a Month of Losses in a Day

Abivax shares surged over 38% after new Phase 3 data for its ulcerative colitis drug, obefazimod, eased cancer-safety fears that had previously caused a significant stock crash. The data showed durable remission with no new safety signals, reassuring investors. While some analyst

Tone
Neutral 50/100
Event
Analyst action
Published
01 Jul 2026 05:10
Source
Market source
StocksToTrade Direct company coverage

ABVX Stock Whipsaws As Obefazimod Delivers Standout Phase 3 Data

Abivax SA (ABVX) stock experienced significant volatility, whipsawing after announcing positive Phase 3 data for its ulcerative colitis drug, obefazimod. The drug showed strong remission rates compared to placebo, meeting key endpoints, but concerns about malignancy cases at the

Tone
Positive 65/100
Event
Macro sensitivity
Published
30 Jun 2026 16:10
Source
StocksToTrade
Proactive financial news Direct company coverage

Abivax shares jump as updated trial data eases safety concerns

Abivax shares surged over 40% after releasing updated safety data for its investigational ulcerative colitis drug, obefazimod. The new analysis showed malignancy rates consistent with background rates in ulcerative colitis patients, easing previous safety concerns that had caused

Tone
Positive 73/100
Event
Regulatory and legal
Published
30 Jun 2026 13:15
Source
Proactive financial news